


REMARKS

In the Office Action of May 19, 2004, the Examiner noted that the Amendment of February 17, 2004 did not comply with the provisions of 37 CFR§1.121 as to the use of the proper identifiers. This Amendment has been prepared on the basis that the Amendments of October 14, 2003 and February 17, 2004 were not entered. The claims have been revised so that all of the proper identifiers have been used in this Amendment. In addition, the Examiner objected to the interchangeable use of the terms "hyaluronic acid" and "hylauroic acid derivative". By this Amendment, the term "hyaluronic acid derivatives" has been adopted throughout the claims. The objection to claims 35 and 36 has been rendered moot by the cancellation of these claims.

An early and favorable action is earnestly solicited.

Respectfully submitted,



James V. Costigan

Reg. No. 25,669

Hedman & Costigan, P.C.
1185 Avenue of the Americas
New York, NY 10036

I hereby certify that this
correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on 9/24/04

